Endometriosis affects approximately 1 in 10 women of reproductive age. In SA's private healthcare system, it is one of the most frequently litigated gynaecological conditions for medical aid coverage — largely because diagnosis is delayed, surgery is expensive, treatment is lifelong, and the condition significantly affects fertility. Understanding what your plan must cover, and where coverage gaps exist, is essential for managing both the medical and financial dimensions of this condition.
What Is Endometriosis?
Endometriosis is a condition in which tissue similar to the uterine lining (endometrium) grows outside the uterus — on the ovaries, fallopian tubes, peritoneum, bowel, bladder, or other structures. This tissue responds to hormonal cycles: it thickens, breaks down, and bleeds with each menstrual cycle but has no exit pathway, causing inflammation, adhesions, and scar tissue formation.
Key clinical features: - Dysmenorrhoea (painful periods): Often severe and worsening over time; a hallmark symptom - Chronic pelvic pain: Persistent pain outside of menstruation - Dyspareunia (painful intercourse) - Subfertility or infertility: Endometriosis accounts for 20–50% of female infertility cases - Bladder and bowel symptoms: Particularly relevant in deeply infiltrating or pelvic wall endometriosis
Endometriosis is staged I–IV (minimal, mild, moderate, severe) at the time of surgical diagnosis. Stage does not always correlate with symptom severity — some women with Stage IV disease have mild symptoms; some with Stage I have debilitating pain.
PMB Coverage
Endometriosis is not a CDL condition. However, surgical treatment — diagnostic laparoscopy and operative laparoscopy (laparoscopic ablation or excision of endometriotic lesions) — is covered under PMB as a hospital procedure. This means your scheme cannot refuse to fund the surgical intervention as a PMB benefit. What it cannot refuse includes the hospitalisation, anaesthesia, and the laparoscopic procedure itself.
PMB coverage does not extend to all ongoing medical management. Post-surgical hormonal suppression therapy, while clinically essential to delay recurrence, is funded through the standard medicine benefit — not PMB. The distinction matters because the medicine benefit is subject to annual limits and formulary restrictions.
Treatment Options
Hormonal suppression therapy — first-line medical management: Endometriosis lesions are oestrogen-dependent. Suppressing ovarian oestrogen production slows lesion activity and reduces pain. Multiple options:
- Combined oral contraceptive pill (continuous/tricyclic use): First-line, inexpensive (~R100–R200/month), available on most formularies
- Norethisterone or medroxyprogesterone acetate (progestogens): Inexpensive; widely available
- Dienogest (Visanne): An endometriosis-specific progestogen with stronger evidence for symptom relief. Monthly cost: approximately R550–R700. Not always on plan formularies — exceptional-needs motivation may be required.
- Levonorgestrel IUD (Mirena): Effective local hormonal suppression; useful when systemic hormonal side effects are a concern. Device + insertion: R4,000–R6,000; lasts 5 years.
- GnRH analogues (goserelin/Zoladex, leuprolide): Create a temporary menopausal state; highly effective but cause significant menopausal side effects; limited to 6-month courses typically due to bone density loss. Monthly cost: R1,800–R2,200. Expensive and require specific authorisation.
- Add-back therapy: Oestrogen/progestogen supplementation to protect bone density during GnRH analogue treatment; adds cost.
Surgical treatment: - Diagnostic laparoscopy: Confirms diagnosis; the only definitive diagnostic test for endometriosis. Requires general anaesthesia. Hospital admission. - Operative laparoscopy (ablation or excision): Removes or destroys endometriotic lesions; treats ovarian endometriomas (chocolate cysts); divides adhesions. The primary curative treatment for symptomatic endometriosis. Excision is preferred over ablation for deep infiltrating disease. - Total hysterectomy with bilateral salpingo-oophorectomy: Definitive treatment for women who have completed their family and have severe, recurrent disease. Not appropriate for women wishing to preserve fertility.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild disease — oral contraceptive only | R5,000 – R15,000 |
| Moderate disease — Visanne + specialist visits | R20,000 – R40,000 |
| GnRH analogue course (6 months) + monitoring | R25,000 – R50,000 |
| Surgical year — diagnostic laparoscopy | R30,000 – R70,000 |
| Surgical year — operative laparoscopy | R40,000 – R90,000+ |
| Hysterectomy year | R60,000 – R120,000+ |
Gap Cover Relevance: High
Laparoscopic surgery is the primary cost trigger. Gynaecologist and laparoscopic surgeon specialist shortfalls range from R20,000–R60,000 per procedure. Critically, endometriosis has a 30–40% surgical recurrence rate within five years — repeat surgery is common, not exceptional. Gap cover with an OPL of approximately R220,000/year is strongly recommended. Many endometriosis patients will use their gap cover OPL in a surgical year.
Fertility and IVF
Endometriosis significantly impairs fertility. If you require assisted reproductive technology (ART/IVF), this is a separate benefit from the endometriosis surgical benefit. Not all plans cover ART. Where it is covered, lifetime benefit limits are typically R50,000–R150,000 — often insufficient for multiple IVF cycles. This is a distinct plan selection consideration.
Plan Selection: Key Questions
- Is laparoscopic surgery funded under the PMB in-hospital benefit with no monetary cap?
- Does the gynaecology specialist consultation benefit cover ongoing specialist review?
- Is dienogest (Visanne) on the formulary, or does it require exceptional-needs/non-formulary motivation?
- Is there a GnRH analogue benefit or does this require exceptional-needs authorisation?
- Is there a separate IVF/ART benefit if fertility is a concern?
Talk to Eldon
See which plans pay for endometriosis →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Staging and Its Limitations
Endometriosis is surgically staged I–IV (ASRM classification): - Stage I (Minimal): Superficial implants, no significant adhesions - Stage II (Mild): Deeper implants, minor adhesions - Stage III (Moderate): Deep implants, endometrioma(s), more significant adhesions - Stage IV (Severe): Extensive deep implants, large endometriomas, dense adhesions
Staging is performed at laparoscopy and documented in the surgical report. The AURA advisory engine uses stage as a proxy for surgical complexity and likely cost trajectory — Stage III–IV patients have substantially higher expected surgical costs and more frequent intervention requirements.